Home › Bids
› Mechanisms that Impact Cancer Risk with Use of Incretin Mime
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
Open267 days leftHealthcaregrant
Nov 18, 2024
Jan 7, 2027 12:00 AM
Healthcare
grant
AI Summary
This grant opportunity (PAR-25-070) from the NIH seeks to fund research into the mechanisms by which incretin mimetics impact cancer risk. Clinical trials are not allowed under this R21 funding mechanism. The CFDA number is 93.393.
Want the full details?
Sign up free to see the agency name, contact info, and the original bid posting link.